Valeant Pharmaceuticals International Inc. (NYSE:VRX) (TSE:VRX) has been assigned a $24.00 target price by equities researchers at Deutsche Bank AG in a note issued to investors on Tuesday. The firm presently has a “hold” rating on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s target price indicates a potential upside of 51.99% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Co. restated a “sell” rating and set a $19.50 target price on shares of Valeant Pharmaceuticals International in a report on Sunday, September 18th. Canaccord Genuity set a $17.00 target price on Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Saturday, November 19th. Scotiabank restated a “sector perform” rating and set a $17.00 target price (down from $32.00) on shares of Valeant Pharmaceuticals International in a report on Thursday, November 10th. Mizuho restated a “neutral” rating and set a $25.00 target price on shares of Valeant Pharmaceuticals International in a report on Tuesday, November 1st. Finally, Piper Jaffray Cos. set a $22.00 target price on Valeant Pharmaceuticals International and gave the company a “sell” rating in a report on Friday, August 19th. Five analysts have rated the stock with a sell rating, thirteen have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $39.05.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 15.79 on Tuesday. The company’s market cap is $5.49 billion. The stock’s 50 day moving average price is $19.47 and its 200 day moving average price is $23.91. Valeant Pharmaceuticals International has a 12-month low of $13.77 and a 12-month high of $119.87.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by $0.23. Valeant Pharmaceuticals International had a positive return on equity of 43.81% and a negative net margin of 22.17%. The firm earned $2.48 billion during the quarter, compared to analysts’ expectations of $2.49 billion. During the same quarter in the previous year, the company posted $2.74 earnings per share. Valeant Pharmaceuticals International’s revenue for the quarter was down 11.0% compared to the same quarter last year. On average, analysts forecast that Valeant Pharmaceuticals International will post $5.44 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and republished in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2016/12/01/valeant-pharmaceuticals-international-inc-vrx-pt-set-at-24-00-by-deutsche-bank-ag.html.

A number of institutional investors have recently added to or reduced their stakes in VRX. D.A. Davidson & CO. increased its position in Valeant Pharmaceuticals International by 22.6% in the third quarter. D.A. Davidson & CO. now owns 5,980 shares of the specialty pharmaceutical company’s stock valued at $146,000 after buying an additional 1,103 shares during the period. Price T Rowe Associates Inc. MD increased its position in Valeant Pharmaceuticals International by 16.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,722,415 shares of the specialty pharmaceutical company’s stock valued at $42,248,000 after buying an additional 239,261 shares during the period. Intl Fcstone Inc. bought a new position in Valeant Pharmaceuticals International during the third quarter valued at $4,804,000. Penn Capital Management Co. Inc. bought a new position in Valeant Pharmaceuticals International during the third quarter valued at $367,000. Finally, Chartwell Investment Partners LLC bought a new position in Valeant Pharmaceuticals International during the third quarter valued at $5,362,000. Institutional investors own 64.97% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.